ADC Therapeutics Gets $50M for Antibody-Drug Conjugates

Start-up firm ADC Therapeutics Sarl has secured funding commitments of up to $50 million to take forward 10 antibody-drug conjugate programs in oncology, based on conjugate and linker chemistry developed by London-based Spirogen Ltd.

To continue reading subscribe now to BioWorld Asia (formerly International)